L3VLUP
ProSign in

ALNY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALNYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALNY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterALNYLLY
Q3 202013 holders, $7.6bn33 holders, $14.1bn
Q4 202013 holders, $6.5bn29 holders, $17.3bn
Q1 202114 holders, $7.2bn24 holders, $23.0bn
Q2 202113 holders, $8.8bn24 holders, $27.8bn
Q3 202114 holders, $9.7bn31 holders, $29.9bn
Q4 202112 holders, $8.8bn31 holders, $34.7bn
Q1 202212 holders, $8.9bn24 holders, $35.3bn
Q2 202213 holders, $8.1bn33 holders, $42.7bn
Q3 202217 holders, $10.8bn31 holders, $43.4bn
Q4 202216 holders, $13.7bn31 holders, $46.6bn
Q1 202319 holders, $11.5bn33 holders, $44.3bn
Q2 202316 holders, $10.6bn37 holders, $59.6bn
Q3 202317 holders, $9.7bn44 holders, $67.6bn
Q4 202315 holders, $10.0bn45 holders, $73.6bn
Q1 202415 holders, $7.3bn41 holders, $95.3bn
Q2 202419 holders, $12.5bn43 holders, $110bn
Q3 202418 holders, $15.1bn45 holders, $107bn
Q4 202415 holders, $12.8bn46 holders, $93.9bn
Q1 202518 holders, $14.9bn42 holders, $98.4bn
Q2 202522 holders, $18.3bn43 holders, $93.2bn
Q3 202533 holders, $26.6bn39 holders, $86.7bn
Q4 202524 holders, $23.4bn41 holders, $123bn
Q1 202622 holders, $17.9bn39 holders, $106bn
Q2 202621 holders, $15.9bn44 holders, $132bn
ALNY

Alnylam Pharmaceuticals Inc

Holders
18
Reported value
$14.9bn
Buyers
11
Sellers
7

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALNY (4)

Baillie Gifford & Co, Soros Fund Management LLC, Two Sigma Investments LP, Voloridge Investment Management LLC

Only LLY (28)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, Egerton Capital UK LLP, Eisler Capital Management Ltd, Element Capital Management LLC, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Lone Pine Capital LLC, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tiger Global Management LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →